Notes
Also see Reactions 1694 p5; 803308159
Reference
European Medicines Agency. PRAC recommends restricting use of prostate cancer medicine Xofigo. Internet Document : [2 pages], 13 Jul 2018. Available from: URL: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Xofigo_20/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500252055.pdf
Rights and permissions
About this article
Cite this article
PRAC recommends restricted use of Xofigo for prostate cancer. Reactions Weekly 1712, 5 (2018). https://doi.org/10.1007/s40278-018-49294-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-49294-2